Matthias Nettekoven

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.

RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.

Journal: Frontiers in pharmacology

Published: May 01, 2024

Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.

Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.

Journal: Molecules (Basel, Switzerland)

Published: August 05, 2019

NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS.

NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS.

Journal: The EMBO journal

Published: November 22, 2017

Challenges and Rewards in Medicinal Chemistry Targeting Cardiovascular and Metabolic Diseases.

Challenges and Rewards in Medicinal Chemistry Targeting Cardiovascular and Metabolic Diseases.

Journal: Chimia

Published: October 29, 2015

Challenges and Rewards in Medicinal Chemistry Targeting Cardiovascular and Metabolic Diseases.

Challenges and Rewards in Medicinal Chemistry Targeting Cardiovascular and Metabolic Diseases.

Journal: Chimia

Published: August 19, 2015

Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases.

Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases.

Journal: ChemMedChem

Published: May 18, 2015

6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds.

6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds.

Journal: Journal of medicinal chemistry

Published: November 02, 2013

Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.

Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.

Journal: Bioorganic & medicinal chemistry letters

Published: December 21, 2012

Aminothiazole derivatives as neuropeptide Y5 receptor ligands: finding the balance between affinity and physicochemical properties.

Aminothiazole derivatives as neuropeptide Y5 receptor ligands: finding the balance between affinity and physicochemical properties.

Journal: ChemMedChem

Published: August 08, 2006

Isomeric thiazole derivatives as ligands for the neuropeptide Y5 receptor.

Isomeric thiazole derivatives as ligands for the neuropeptide Y5 receptor.

Journal: Bioorganic & medicinal chemistry letters

Published: March 07, 2005

Accelerating drug discovery by integrative implementation of laboratory automation in the work flow.

Accelerating drug discovery by integrative implementation of laboratory automation in the work flow.

Journal: Current medicinal chemistry

Published: December 10, 2002

Combinatorial synthesis of libraries of indole derivatives.

Combinatorial synthesis of libraries of indole derivatives.

Journal: Bioorganic & medicinal chemistry letters

Published: August 22, 2001

Showing 1-12 of 12

Last Updated: 09/26/2026